Stock Scorecard



Stock Summary for Zai Lab Ltd (ZLAB) - $17.91 as of 6/16/2026 7:02:39 PM EST

Total Score

11 out of 30

Safety Score

25 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for ZLAB

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for ZLAB

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for ZLAB

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for ZLAB

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for ZLAB (25 out of 100)

Stock Price Rating (Max of 10) 6
Historical Stock Price Rating (Max of 10) 8
Stock Price Trend (Max of 10) 2
Book Value (Max of 10) 4
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 6
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) -10

Latest News for for ZLAB

EMA grants orphan status to lung NEC drug for 375,000 patients 6/16/2026 10:40:00 AM
Number of shareholders of Zai Lab Ltd. Sponsored ADR – SWB:1ZL 6/15/2026 6:39:00 AM
TCG Crossover funds, Chen Yu hold 5.3% of ZLAB (ADS positions) 6/12/2026 12:40:00 AM
China’s TIVDAK Approval in Advanced Cervical Cancer Could Be A Game Changer For Zai Lab (ZLAB) 6/11/2026 12:39:00 PM
China’s TIVDAK Approval in Advanced Cervical Cancer Could Be A Game Changer For Zai Lab (ZLAB) 6/10/2026 3:39:00 PM
Zai Lab (ZLAB) Gains Approval for Tivdak in Cervical Cancer Treatment 6/9/2026 1:10:00 PM
Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer 6/9/2026 12:09:00 PM
Zai Lab wins China NMPA approval for cervical cancer drug TIVDAK 6/9/2026 12:09:00 PM
Assessing Zai Lab (ZLAB) Valuation After China Approval Of TIVDAK For Advanced Cervical Cancer 6/9/2026 7:09:00 AM
Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer 6/9/2026 12:09:00 AM

Financial Details for ZLAB

Company Overview

Ticker ZLAB
Company Name Zai Lab Ltd
Country N/A
Description Zai Lab Limited, a biopharmaceutical company, discovers, licenses, develops and markets therapies to treat cancer, autoimmune and infectious diseases in China. The company is headquartered in Shanghai, China.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 3/31/2026
Next Earnings Date N/A

Stock Price History

Last Day Price 17.91
Price 4 Years Ago 30.70
Last Day Price Updated 6/16/2026 7:02:39 PM EST
Last Day Volume 637,971
Average Daily Volume 918,874
52-Week High 41.20
52-Week Low 15.96
Last Price to 52 Week Low 12.22%

Valuation Measures

Trailing PE N/A
Industry PE 28.45
Sector PE 58.71
5-Year Average PE -15.34
Free Cash Flow Ratio 3.09
Industry Free Cash Flow Ratio 16.77
Sector Free Cash Flow Ratio 26.28
Current Ratio Most Recent Quarter 2.40
Total Cash Per Share 5.80
Book Value Per Share Most Recent Quarter 6.47
Price to Book Ratio 3.00
Industry Price to Book Ratio 4.38
Sector Price to Book Ratio 7.14
Price to Sales Ratio Twelve Trailing Months 4.28
Industry Price to Sales Ratio Twelve Trailing Months 9.39
Sector Price to Sales Ratio Twelve Trailing Months 9.27
Analyst Buy Ratings 9
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 112,355,000
Market Capitalization 2,012,278,050
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 31.73%
Reported EPS 12 Trailing Months -1.70
Reported EPS Past Year -0.46
Reported EPS Prior Year -1.61
Net Income Twelve Trailing Months -178,115,000
Net Income Past Year -175,537,000
Net Income Prior Year -257,103,000
Quarterly Revenue Growth YOY -6.50%
5-Year Revenue Growth 56.54%
Operating Margin Twelve Trailing Months -69.70%

Balance Sheet

Total Cash Most Recent Quarter 651,316,000
Total Cash Past Year 679,573,000
Total Cash Prior Year 449,667,000
Net Cash Position Most Recent Quarter 651,316,000
Net Cash Position Past Year 679,573,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 715,500,000
Total Stockholder Equity Prior Year 840,898,000
Total Stockholder Equity Most Recent Quarter 661,981,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -129,228,000
Free Cash Flow Per Share Twelve Trailing Months -1.15
Free Cash Flow Past Year -158,890,000
Free Cash Flow Prior Year -276,391,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.00
MACD Signal 0.00
20-Day Bollinger Lower Band 15.75
20-Day Bollinger Middle Band 19.43
20-Day Bollinger Upper Band 23.12
Beta 0.78
RSI 33.84
50-Day SMA 0.00
150-Day SMA 0.00
200-Day SMA 0.00

System

Modified 6/16/2026 11:48:40 AM EST